

MolMed S.p.A.: mandate of Liquidity Provider assigned to Mediobanca

Milan, July 3, 2017 – MolMed S.p.A. and Mediobanca - Banca di Credito Finanziario S.p.A today signed a contract outlining the assignment of the mandate of Liquidity Provider aimed to support liquidity of its ordinary shares, pursuant to the provision of Consob resolution n. 16839 dated 19.03.2009.

The summary information relating to the liquidity provider mandate (activity performed with risk undertaken by the issuer) is set forth below, in accordance with the aforesaid Consob Resolution.

Appointed intermediary	Mediobanca – Banca di Credito Finanziario S.p.A., registered office in Milan, 1 Piazzetta Enrico Cuccia
Mediobanca's dealer code	0362
Activity starting date	10/07/2017
Market on which the activity is performed	Mercato Telematico Azionario (MTA) of the Milan stock exchange managed by Borsa Italiana
Maximum limits for open positions*	Purchase: 2% of the shares issued Sale: 2% of the shares issued

*These limits may be exceeded only in the cases permitted by Consob Resolution 16839.

Banca IMI ceased operating as liquidity provider for MolMed on June 4th, 2017

This press release is written in compliance with public disclosure obligations established by Consob's (Italian securities & exchange commission) Issuers Regulation.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 20.312.682,30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6, an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

For further information:

Laura Villa

Investor Relations & Communication Director

MolMed S.p.A.

telefono: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@segrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..